Recommendations for the treatment of multiple sclerosis with disease-modifying drugs during the COVID-19 pandemic by R. Kizlaitienė, N. Giedraitienė, I. Sereikė, J. Liutkienė, L. Leščinskienė, G. Kaubrys

Subjects: Get full text

Corrigendum: Shifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies by Alexander J. O’Donovan, Seth Gorelik, Seth Gorelik, Laura M. Nally

Subjects: Get full text

Shifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies by Alexander J. O’Donovan, Seth Gorelik, Seth Gorelik, Laura M. Nally

Subjects: Get full text

Adherence to disease modifying therapies in patients with multiple sclerosis by D. Pileckė, N. Giedraitienė

Subjects: Get full text

Administration and Monitoring Burden of High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis: A Delphi Consensus of Clinical Experts from Saudi Arabia by Seraj Makkawi, Ahmad Abulaban, Yaser Al Malik, Ebtesam Alshehri, Ahmed Althobaiti, Salman Aljarallah, Ahmed Elboghdady, Lynn AlHajjar, Sahar Shami, Saeed Bohlega, Mohammed Aljumah

Subjects: Get full text